国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2012年
15期
2235-2237
,共3页
经皮肾镜%肾结石%肾盂输尿管连接部狭窄
經皮腎鏡%腎結石%腎盂輸尿管連接部狹窄
경피신경%신결석%신우수뇨관련접부협착
Percutaneous nephrolithotomy%Renal calculi%Ureteropelvic junction stenosis
目的 分析并探讨经皮肾镜治疗肾结石合并肾盂输尿管连接部狭窄的临床治疗效果.方法 对我院2008年5月至2011年5月期间采用经皮肾镜技术治疗肾结石合并肾盂输尿管连接部狭窄共计56例患者的临床资料进行回顾性分析,对其治疗效果进行总结和探讨.结果 所有患者均一期完成手术,手术时间为60~110 min,术中出血量50~150 ml,无严重并发症发生.术后随访发现患者症状均有不同程度减轻,患者患肾积水均较前减轻.结论 采用经皮肾镜术治疗肾结石疗效显著、安全性好、恢复快、并发症发生率低、结石清除率高,是治疗肾结石合并肾盂输尿管连接部狭窄的一线疗法.
目的 分析併探討經皮腎鏡治療腎結石閤併腎盂輸尿管連接部狹窄的臨床治療效果.方法 對我院2008年5月至2011年5月期間採用經皮腎鏡技術治療腎結石閤併腎盂輸尿管連接部狹窄共計56例患者的臨床資料進行迴顧性分析,對其治療效果進行總結和探討.結果 所有患者均一期完成手術,手術時間為60~110 min,術中齣血量50~150 ml,無嚴重併髮癥髮生.術後隨訪髮現患者癥狀均有不同程度減輕,患者患腎積水均較前減輕.結論 採用經皮腎鏡術治療腎結石療效顯著、安全性好、恢複快、併髮癥髮生率低、結石清除率高,是治療腎結石閤併腎盂輸尿管連接部狹窄的一線療法.
목적 분석병탐토경피신경치료신결석합병신우수뇨관련접부협착적림상치료효과.방법 대아원2008년5월지2011년5월기간채용경피신경기술치료신결석합병신우수뇨관련접부협착공계56례환자적림상자료진행회고성분석,대기치료효과진행총결화탐토.결과 소유환자균일기완성수술,수술시간위60~110 min,술중출혈량50~150 ml,무엄중병발증발생.술후수방발현환자증상균유불동정도감경,환자환신적수균교전감경.결론 채용경피신경술치료신결석료효현저、안전성호、회복쾌、병발증발생솔저、결석청제솔고,시치료신결석합병신우수뇨관련접부협착적일선요법.
Objective To analyze and explore the clinical efficacy of percutaneous nephrolithotomy for renal calculi complicating with ureteropelvic junction stenosis.Methods The clinical data of 56 patients with renal calculi complicating with ureteropelvic junction stenosis undergoing percutaneous nephrolithotomy from our hospital from May 2008 to May 2011 retrospectively analyzed.The clinical efficacy was summarized and discussed.Results all patients' operations were completed in one stage operation with 60-110 minutes operation time.Bleeding volume during operation was 50-150 ml.No serious complications occurred.Postoperative follow-up revealed patients symptoms had different degrees of ease and patients with hydronephrosis were relieved.Conclusions Percutaneous nephrolithotomy for renal calculi is significantly efficacious,safe,fast recovery and has low complication rate and high stone-free rate.It's a first-line therapy for renal calculi complicating with ureteropelvic junction stenosis.